

1 **Supplementary Table S5: Serum pharmacokinetic parameters for botensilimab following**
 2 **once weekly intravenous administration at 5, 25, or 75 mg/kg/dose to male and female**
 3 **cynomolgus monkeys for 13 weeks.**

Dose (mg/kg)	Study Day	Sex	Cmax (µg/mL)	Tmax (h)	AUC0-last (h*µg/mL)	T1/2 (h)	Cl (mL/h/kg)	Vss (mL/kg)	AUC0-inf (h*µg/mL)
5	1	M	314 ± 123	1.2 (0.3 - 1.2)	18,700 ± 4,900	213.6	0.137	36.2	40,300
		F	2960 ± 70.8	0.4 (0.3 - 1.2)	22,400 ± 60,200	187.4	0.117	29.9	43,900
	85	M	591	1.2	57,400	159	0.046	8.72	128,000
		F	478 ± 355	0.4 (0.3 - 8.2)	46,800 ± 46,100	181.5	3.31	30.3	93,900
25	1	M	969 ± 79.8	0.3 (0.3 - 1.2)	74,100 ± 12,000	146.7 (107.8 - 407.5)	0.147 ± 0.052	39.3 ± 14.2	185,000 ± 64,900
		F	9910 ± 204	0.4 (0.3 - 1.2)	71,300 ± 15,300	130.1 (96.6 - 135.3)	0.198 ± 3.01	34.7 ± 6.18	135,000 ± 38,800
	85	M	1300 ± 596	0.4 (0.3 - 1.2)	92,300 ± 77,800	106.8 (4.5 - 332.1)	1.82 ± 3.01	24.9 ± 8.10	257,000 ± 286,000
		F	1980 ± 105	0.3 (0.3 - 0.4)	187,000 ± 5,300	214.7 (193.2 - 342.9)	0.045 ± 0.009	15.7 ± 1.19	569,000 ± 131,000
75	1	M	3050 ± 633	1.2 (0.4 - 1.2)	217,000 ± 59,500	120.0 (114.9 - 171.1)	0.219 ± 0.110	39.5 ± 15.0	391,000 ± 132,000
		F	2980 ± 281	0.4 (0.3 - 1.2)	225,000 ± 27,700	153.5 (133.4 - 271.9)	0.152 ± 0.0436	36.8 ± 5.37	524,000 ± 139,000
	85	M	5480 ± 810	0.4 (0.4 - 1.2)	456,000 ± 92,200	100.3 (94.3 - 134.9)	0.098 ± 0.026	15.7 ± 2.72	805,000 ± 225,000
		F	5520 ± 1200	0.4 (0.3 - 1.2)	422,000 ± 94,600	104.1 (98.1 - 142.9)	0.108 ± 0.034	17.5 ± 3.59	752,000 ± 242,000

4 PK parameters derived from a multi-dose intravenous administration of botensilimab to male (M)
 5 and female (F) cynomolgus monkeys. Cl = clearance, Cmax = maximum concentration, AUC(0-
 6 last) = area under curve to last, AUC (0-∞) = area under curve to infinity, T1/2 = half-life, Tmax =
 7 time to maximum, and Vss = volume at steady state.